Journal of cardiology · 2010
What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation?
Сравнительное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Park Keun-Ho, Jeong Myung Ho, Lee Min Goo, Ko Jum Suk, Sim Doo Sun, Yoon Nam Sik, Yoon Hyun Ju, Hong Young Joon, Kim Kye Hun, Park Hyung Wook, Kim Ju Han, Ahn Youngkeun, Cho Jeong Gwan, Park Jong Chun, Kang Jung Chaee
Аннотация
BACKGROUND: The optimal duration of triple anti-platelet therapy (DTAP) remains unclear in patients with acute myocardial infarction (AMI).
METHODS: We retrospectively analyzed 716 AMI patients who received TAP (aspirin, clopidogrel, and cilostazol) after drug-eluting stent (DES) implantation from November 2005 to May 2008. Mean age was 61.9 ± 11.70 years (male gender 74.1%) and mean duration of TAP was 98.1 ± 115.34 days. We compared the major adverse cardiovascular events [MACE, defined as the composite of cardiac death, non-fatal AMI, stent thrombosis, and target vessel revascularization (TVR)] between the group of DTAP ≥ 3 months (n = 497) and those of < 3 months (n = 219).
RESULTS: There were no significant differences in the incidences of cardiac death, non-fatal AMI, stent thrombosis, and TVR at 1-year follow-up between the two groups. However, the group of DTAP ≥ 3 months had lower incidence of MACE than those < 3 months (5.9% vs. 10.7%, p = 0.044). The rate of bleeding complications was similar between the two groups. By Cox regression analysis with propensity score adjustment, Killip class IV and DTAP ≥ 3 months were independent predictors of 1-year MACE [hazard ratio (HR) = 10.417; 95% confidence interval (CI) = 1.587-68.377, p = 0.015 and HR = 0.508; 95% CI = 0.269-0.956, p = 0.036].
CONCLUSIONS: Our data show that the DTAP ≥ 3 months is associated with better clinical outcomes compared with that of < 3 months in patients with AMI undergoing DES implantation without increasing bleeding complications.
METHODS: We retrospectively analyzed 716 AMI patients who received TAP (aspirin, clopidogrel, and cilostazol) after drug-eluting stent (DES) implantation from November 2005 to May 2008. Mean age was 61.9 ± 11.70 years (male gender 74.1%) and mean duration of TAP was 98.1 ± 115.34 days. We compared the major adverse cardiovascular events [MACE, defined as the composite of cardiac death, non-fatal AMI, stent thrombosis, and target vessel revascularization (TVR)] between the group of DTAP ≥ 3 months (n = 497) and those of < 3 months (n = 219).
RESULTS: There were no significant differences in the incidences of cardiac death, non-fatal AMI, stent thrombosis, and TVR at 1-year follow-up between the two groups. However, the group of DTAP ≥ 3 months had lower incidence of MACE than those < 3 months (5.9% vs. 10.7%, p = 0.044). The rate of bleeding complications was similar between the two groups. By Cox regression analysis with propensity score adjustment, Killip class IV and DTAP ≥ 3 months were independent predictors of 1-year MACE [hazard ratio (HR) = 10.417; 95% confidence interval (CI) = 1.587-68.377, p = 0.015 and HR = 0.508; 95% CI = 0.269-0.956, p = 0.036].
CONCLUSIONS: Our data show that the DTAP ≥ 3 months is associated with better clinical outcomes compared with that of < 3 months in patients with AMI undergoing DES implantation without increasing bleeding complications.